The healthcare giants Johnson & Johnson has confirmed that their vaccine is 85% more effective in most serious symptoms. Moreover, the vaccine is administered only one injection and doesn’t need two doses, unlike other vaccines. Moreover, the company’s latest tests also show that it’s 66% effective overall in severe COVID-19 symptoms.
If the vaccine gets approval, then it’ll follow other vaccines like AstraZeneca, Pfizer and Moderna. Currently, the rollout for this vaccine is expected in the second half of 2021’s vaccine rollout.
This vaccine from J&J is quite cheap compared to other vaccines as it’ll only cost 10$ or 7£. Moreover, it also requires to be kept at fridge temperature. Thus, the handling or storage of such vaccine won’t be an issue as well.
A vaccine of hope?
J&J’s Chief Scientific Officer Paul Stoffels added that the results with a single vaccine shot are very promising. In addition, it has the potential to reduce the burden of severe disease and can become a critical component of global public health.
Currently, WHO is also considering one-shot vaccines as the best option to tackle this pandemic. Also, its 85% efficiency can save millions of people worldwide from serious outcomes of COVID-19.
The Chief Scientific Officer also added that this vaccine could offer the hope of easing the huge burden on healthcare services and communities.